Injectables

Botox vs Xeomin: Which Neuromodulator to Stock and Offer Your Patients

Q: What's the cost difference between Botox and Xeomin per treatment?

A 20-unit Botox treatment costs roughly $200–260, while the equivalent Xeomin dose (24–26 units) runs $192–286. Wholesale pricing ranges from $10–13 per unit for Botox and $8–11 per unit for Xeomin, though rebate programs like Alle and Evolus Rewards can significantly narrow the gap at higher volumes.

Q: Does Xeomin really work faster than Botox?

Yes, Xeomin typically shows results in 48–72 hours versus Botox's 72–96 hours, but the difference is modest. Both reach full effect around day 7–10, so for routine cosmetic patients the speed difference is negligible—it only matters for event-driven cases with tight timelines.

Q: What does 'naked toxin' mean and why does it matter?

Xeomin is formulated without the accessory proteins that Botox contains, earning it the 'naked toxin' label. This protein-free formulation theoretically allows faster onset and potentially broader diffusion, though it requires higher unit doses to match Botox's clinical effect.

Q: Can patients develop resistance to Botox or Xeomin?

Both products carry a small risk of antibody formation, though it occurs in less than 1% of users. Xeomin's naked formulation was originally thought to reduce this risk, but long-term data show similar immunogenicity rates between the two products.

Q: Should I stock both Botox and Xeomin or just one?

Most successful practices stock both to offer patient choice and flexibility. Botox is ideal for high-volume, predictable results; Xeomin works well for patients requesting faster onset or when you want a differentiated brand positioning. Your acquisition cost structure and rebate tier eligibility should also factor into the decision.

Both are FDA-approved botulinum toxin Type A products, but their formulations, onset profiles, dosing economics, and patient candidacy differ in ways that matter to your bottom line and clinical outcomes.

Botox vs Xeomin: Which Neuromodulator to Stock and Offer Your Patients

Photo: Hannah Barata / Pexels

AI Inside MedSpa Intelligence · Jun 26, 2026

Botox and Xeomin are both FDA-cleared botulinum toxin Type A (BoNT-A) neuromodulators, but they are not interchangeable. The critical difference lies in their formulation: Botox is complexed with accessory proteins (100 units per 1 mL vial), while Xeomin is a naked toxin—stripped of those proteins during manufacturing. That distinction drives differences in onset speed, dosing requirements, patient response, and your acquisition cost.

Formulation and the Protein Complex Question

Botox's accessory proteins may slow diffusion across the neuromuscular junction, which some clinicians argue provides a tighter, more predictable zone of effect. Xeomin's protein-free formulation theoretically allows faster onset and potentially broader diffusion, though clinical data on diffusion differences remain mixed. The practical implication: Xeomin users often report seeing results in 2–3 days versus Botox's typical 3–5 days, though full effect for both arrives around day 7–10. This matters when patients want rapid results before an event.

Dosing and Unit Economics

Here is where the math gets real. Xeomin requires approximately 1.2 to 1.3 times the units of Botox to achieve equivalent clinical effect—a phenomenon attributed to the absence of the protein complex. If you're treating a glabellar region with 20 units of Botox, you'll typically use 24–26 units of Xeomin.

On a per-unit basis, Xeomin has historically been priced lower than Botox, but the higher unit requirement can offset that advantage. Current wholesale pricing (verify with your supplier and loyalty program) typically ranges:

Botox: $10–13 per unit (depending on volume tier and rebate structure via Alle or Aspire)
Xeomin: $8–11 per unit (Evolus Rewards program pricing varies)

A 20-unit Botox treatment costs roughly $200–260; the equivalent Xeomin dose (24–26 units) runs $192–286. The gap narrows when you factor in rebate tiers. If you're moving high volume, Botox's Alle rebate program can push per-unit cost below $10; Evolus's Rewards program offers similar incentives but requires hitting different thresholds.

Onset and Patient Expectations

Compared	Botox	Xeomin
Formulation	Botulinum toxin Type A with accessory proteins	Botulinum toxin Type A (naked toxin, protein-free)
Onset	3–5 days; full effect day 7–10	2–3 days; full effect day 7–10
Dosing / units	Standard reference dose (e.g., 20 units glabellar)	1.2–1.3× Botox units for equivalent effect (e.g., 24–26 units glabellar)
Cost basis (per unit)	$10–13/unit (Alle rebate program can push below $10 at volume)	$8–11/unit (Evolus Rewards program; varies by tier)
Cost per treatment	~$200–260 for 20-unit glabellar treatment	~$192–286 for 24–26 unit equivalent (offset by higher unit requirement)
FDA status	FDA-cleared; 20+ years cosmetic use history	FDA-cleared botulinum toxin Type A
Antibody resistance risk	<1% of users; similar to Xeomin	<1% of users; similar to Botox
Best for	High-volume, predictable results; established patient base; rebate optimization	Event-driven cases; faster onset preference; differentiated 'naked toxin' positioning

Bottom line: Choose Botox for high-volume, cost-optimized practices with established patient bases; choose Xeomin when patients prioritize faster onset or you seek portfolio differentiation and favorable unit pricing through your supplier structure.

Xeomin requires 1.2–1.3× the units of Botox for equivalent effect, which can offset its lower per-unit cost depending on your rebate tier.

Xeomin's faster onset (48–72 hours vs. 72–96 hours for Botox) is clinically real but modest. For routine cosmetic patients, the difference is negligible. For event-driven cases—a wedding in 5 days—Xeomin edges ahead. Set expectations clearly either way; neither product is "instant."

Antibody Formation and Resistance

Both products carry a small risk of antibody formation against the toxin, rendering future treatments less effective. The naked formulation of Xeomin was originally thought to reduce immunogenicity, but long-term clinical data suggest the risk is similar. If a patient develops resistance (rare, <1% of users), switching between BoNT-A products (Botox, Xeomin, Daxxify) may restore response, though this is not guaranteed.

Patient Fit and Clinical Scenarios

Offer Botox if: you're treating high-volume patients seeking predictable, tight results; your patient base values the longest track record (Botox has 20+ years of cosmetic use); you're optimizing for rebate economics at scale.

Offer Xeomin if: patients specifically request faster onset; you're building a differentiated clinical brand around "naked toxin" messaging; you want flexibility in your toxin portfolio; your acquisition cost is meaningfully lower through your group purchasing or MSO structure.

Practical Recommendation

Most successful practices stock both. Botox remains the volume driver and the default for most patients—it's what they've heard of, what their friends use, and what carries the deepest clinical literature. Xeomin serves as a premium option for onset-sensitive patients and as a backup for those who may have developed antibodies to Botox. The dosing adjustment (1.2–1.3× multiplier) is straightforward to train staff on, and the clinical outcomes are equivalent at proper dosing.

Your choice ultimately hinges on your cost structure, patient demographics, and whether you're pursuing a multi-product strategy. If you're an MSO or group practice, negotiate both into your GPO agreement; the competitive pressure between AbbVie (Botox) and Evolus (Xeomin) works in your favor.

Frequently asked questions

How many units of Xeomin do I need compared to Botox?

Xeomin requires approximately 1.2 to 1.3 times the units of Botox to achieve equivalent results. For example, a 20-unit Botox treatment typically requires 24–26 units of Xeomin. This higher unit requirement is due to Xeomin's protein-free formulation.

What's the cost difference between Botox and Xeomin per treatment?

A 20-unit Botox treatment costs roughly $200–260, while the equivalent Xeomin dose (24–26 units) runs $192–286. Wholesale pricing ranges from $10–13 per unit for Botox and $8–11 per unit for Xeomin, though rebate programs like Alle and Evolus Rewards can significantly narrow the gap at higher volumes.

Does Xeomin really work faster than Botox?

Yes, Xeomin typically shows results in 48–72 hours versus Botox's 72–96 hours, but the difference is modest. Both reach full effect around day 7–10, so for routine cosmetic patients the speed difference is negligible—it only matters for event-driven cases with tight timelines.

What does 'naked toxin' mean and why does it matter?

Xeomin is formulated without the accessory proteins that Botox contains, earning it the 'naked toxin' label. This protein-free formulation theoretically allows faster onset and potentially broader diffusion, though it requires higher unit doses to match Botox's clinical effect.

Can patients develop resistance to Botox or Xeomin?

Both products carry a small risk of antibody formation, though it occurs in less than 1% of users. Xeomin's naked formulation was originally thought to reduce this risk, but long-term data show similar immunogenicity rates between the two products.

Should I stock both Botox and Xeomin or just one?

Most successful practices stock both to offer patient choice and flexibility. Botox is ideal for high-volume, predictable results; Xeomin works well for patients requesting faster onset or when you want a differentiated brand positioning. Your acquisition cost structure and rebate tier eligibility should also factor into the decision.

Free weekly brief

Get the free weekly brief.

The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.